Business
Harvest One Cannabis Inc. - Favourable Results from Phase 2 Clinical Trials using Satipharm Capsules
Harvest One Cannabis Inc. - Favourable Results from Phase 2 Clinical Trials using Satiphar...
About this update from Delivra Health Brands Inc
[{"type":"text","content":"\n\n\n\nHarvest One Cannabis Inc. - Favourable Results from Phase 2 Clinical Trials using Satipharm Capsules\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Feb. 1, 2018\n\n\n\nTSXV – HVST                                                                                               \n\n\n\nVANCOUVER, Feb. 1, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVST) (\"Harvest One\" or the \"Company\") through its wholly-owned subsidiary Satipharm AG (\"Satipharm\") is pleased to announce its proprietary capsules were used in a Phase 2 Clinical Trials undertaken by Israeli-based PhytoTech Therapeutics Ltd (\"PTL\") a wholly owned subsidiary of MMJ PhytoTech limited (\"MMJ\"). The Phase 2 trial is an open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of oral administration of Satipharm CBD capsules as an adjunctive treatment. Results from the first 10 patients who participated in the Phase 2 clinical trials are now available.\n\n\n \n \n\n \nHighlights:\n\n\nPTL's Phase 2 open label clinical trial is aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant, epilepsy.\nSatipharm CBD capsules are a proprietary oral formulation developed using the Gelpell-CBD™ product technology.\nSatipharm CBD capsules reduced monthly seizure frequency in the treatment-resistant children when added to current medications. The treatment was generally well tolerated, with a safety profile consistent with prior experience.\nPromising evidence of efficac...